For patients with locally advanced basal cell carcinoma (laBCC)

# The only hedgehog pathway inhibitor with 2 years of response^{1}

Objective Response Rate (ORR): 56% (n=37/66; 95% CI: 43-68). ORR=Complete Response (CR of
5%, n=3) + Partial Response (PR of 52%, n=34).^{1}*

Median Duration of Response: 26.1 months (95% CI: 10.1 months, not reached).^{1}

About the BOLT trial: A multicenter (58 centers, 12 countries), randomized, double-blind,
phase II trial evaluating once-daily dosing of ODOMZO in 194 patients with laBCC. Patients were randomized
1:2 to the 200 mg or 800 mg dose.^{1,2}

*All modalities used must have demonstrated absence of tumor to achieve a composite assessment of CR. PR is
defined as ≥50% decrease in the sum of the product of perpendicular diameters (SPD) of the lesions by photo
assessment and ≥30% decrease in the sum of diameters of lesions per MRI.^{1,2}